Krystal Biotech, Inc. — Director's Dealing 2017

Sep 20, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-19

Reporting Person: JANNEY DANIEL (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	130590	Direct
Series A Convertible Preferred Stock	124456	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$11.07	2026-11-09	Common Stock (37894)		Direct

Footnotes

F1: The Series A convertible preferred stock will automatically convert on a one-to-one basis into 124,456 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.

F2: Represents shares owned by Alta Bioequities, L.P., an investment entity owned and controlled by the reporting person.

F3: The options were awarded on November 10, 2016 and vest ratably over a four-year period.